Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias

Summary

The primary objective of this study is to determine the maximum tolerated dose, dose limiting toxicity, safety and tolerability of TH-302 in patients with acute leukemias, advanced phase chronic myelogenous leukemia (CML), high risk myelodysplastic syndromes, advanced myelofibrosis or relapsed/refractory chronic lymphocytic leukemia (CLL).

Timeline

Start

2010-06

Primary completion

2013-08

Completion

2013-08

Drugs

Indications